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FAM46DCancer/testis Antigens (CTAs) are immunogenic proteins with a restricted expression pattern in normal
tissues and aberrant expression in different types of tumors being considered promising candidates for
immunotherapy. We used the alignment between EST sequences and the human genome sequence to
identify novel CT genes. By examining the EST tissue composition of known CT clusters we deﬁned
parameters for the selection of 1184 EST clusters corresponding to putative CT genes. The expression pattern
of 70 CT gene candidates was evaluated by RT-PCR in 21 normal tissues, 17 tumor cell lines and 160 primary
tumors. We were able to identify 4 CT genes expressed in different types of tumors. The presence of
antibodies against the protein encoded by 1 of these 4 CT genes (FAM46D) was exclusively detected in
plasma samples from cancer patients. Due to its restricted expression pattern and immunogenicity FAM46D
represents a novel target for cancer immunotherapy.© 2009 Elsevier Inc. All rights reserved.Introduction
Cancer/testis (CT) genes are expressed in the germ cells of testis
and fetal ovary and in different histological types of tumors [1–4].
So far, more than 83 distinct CT gene families have been described,
most of them are located on the X chromosome [1]. Most CT genes
have been shown to encode proteins that are immunogenic (CT
Antigens or CTA), eliciting both humoral and cellular immune
responses in cancer patients [1]. Due to their restricted expression
pattern and immunogenicity, CTAs are considered promising
candidates for the development of therapeutic cancer vaccines.
Advanced clinical trials with CTA vaccines are currently underway
to access their efﬁcacy in delaying or preventing recurrence of
melanoma and lung cancer following surgical removal of primary
tumors [5–8].sited with the DDBJ/EMBL/
37578, EF537579, EF537580,
rgo).
ll rights reserved.However, some characteristics shared by this group of proteins
may represent challenges to the development of a universal cancer
vaccine. Firstly, the expression frequency of a speciﬁc CT antigen is
highly variable between different types of tumors. Second, the
expression of a given CTA within a tumor is highly heterogeneous,
with tumors showing single positive cells or small groups of positive
cells to others with a homogeneous expression pattern. Finally,
tumors frequently develop mechanisms to evade the host immune
system and antigen loss is frequently observed in tumors.
One way to overcome tumor heterogeneity and immune escape is
to design polyvalent cancer vaccines containing epitopes derived from
different CTAs. The identiﬁcation of a large repertoire of CTAs that
could be incorporated in polyvalent cancer vaccines is thus critical for
improving current immunotherapy protocols. Most of the known CTAs
were identiﬁed using immunological screening methods such as T-
lymphocyte epitope cloning and SEREX (Serological analysis of cDNA
expression libraries) [9–14]. However, due to their characteristic
expression pattern, non-immunological techniques, relying on differ-
ential mRNA expression, have also been successfully used for the
characterization of novel CT genes. Methods including RDA (Repre-
sentational Difference Analysis), Differential Display and cDNA micro-
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testis and different tumor types, such as LAGE-1/CTAG2, CT10/
MAGEC2, CTp11, SPANX-C1/SPANXA1, MMA-1A/DSCR8 and DBL/MCF2
[15–19]. These CT genes were later shown to encode immunogenic
proteins recognized by the immune system of cancer patients.
Computational approaches have also been used for the identiﬁcation
of CT genes. In a pioneer study, Scanlan et al. [20] mined the UniGene
database for gene clusters composed of expressed sequence tags (ESTs)
generated from normal testis and tumor-derived cDNA libraries. A total
of 1325gene clusterswere initially selected as corresponding to putative
CTgenes based on their ESTcomposition. After assessing the expression
pattern of 73 candidate clusters by RT-PCR, three novel CT genes (CT15/
ADAM2, CT16/PAGE5 and CT17/LIPI) were identiﬁed.
Using a similar strategy, Chen et al. [21] analyzed MPSS (Massively
Parallel Signature Sequencing) expression data from 32 normal
human tissues and identiﬁed 1056 genes that were predominantly
expressed in normal testis. Further evaluation using MPSS tags from
tumor cell lines and EST data from awide variety of tumors, identiﬁed
202 of these 1056 genes as candidates for encoding novel CT genes
based on their expression pattern. RT-PCR validation was carried out
for a subset of 166 intron-containing candidates using cDNAs from
normal testis and 21 tumor cell lines. Twenty candidates were
validated as novel CT genes based on their expression pattern.
Finally, in a recent work Hofmann et al. [22] have used an in silico
approach that combined expression information from different plat-
forms (including ESTs, MPSS and Cap-analysis of Gene Expression) to
produce a comprehensive survey of the expression proﬁle of 153
previously described CT genes. By applying this strategy in a genome-
wide survey for novel CT genes they identiﬁed over 30 CT candidate
genes, of which 3 (PEPP-2/RHOXF2, OTOA and AKAP4) were conﬁrmed
to be predominantly expressed in testis and tumor cell lines by RT-PCR.
In the present work, we combined in silico and experimental
evaluation of gene expression with serological analysis of cancer
patients to identify novel CTAs. Using this approach, we were able to
identify 4 CT genes frequently expressed in different types of tumors.
The presence of speciﬁc antibodies recognizing the protein encoded
by 1 of these 4 CTgenes (FAM46D) was exclusively detected in plasma
samples from cancer patients. Due to its restricted expression pattern
and immunogenicity FAM46D represents a novel target for cancer
immunotherapy. An additional CT gene candidate (PASD1) was
described during the expression evaluation step of this work as a
novel CTA frequently expressed in B-cell lymphomas [23]. Information
presented in this manuscript on the high frequency of PASD1
expression in different types of solid tumors and immunogenicity in
patients with cervix tumors and glioblastomas also supports PASD1 as
a promising target for cancer immunotherapy.
Results
EST composition of clusters corresponding to known CTAs
ESTs can be used to identify new genes [24–28], to construct gene-
based physical maps [29,30], to compare and annotate genomes of
different organisms [31–33] and to study different aspects of mRNA
structure such as splicing [34–39] and polyadenylation variants [40–42].
ESTs can also be used to qualitatively and quantitatively determine
gene expression proﬁles if one considers the tissue source of the cDNA
libraries and the frequencyof ESTs corresponding to a given transcript in
a cDNA library, respectively. In the present work, we have used the
publicly available human genome sequence to cluster ESTs derived from
a same gene. We were then able to select clusters composed by ESTs
derived from testis and tumor cDNA libraries thatwould representnovel
CT genes.
To address possible limitations of our strategy, we ﬁrst evaluated
the EST tissue composition of clusters corresponding to 20 known
CTAs (MAGEA1, MAGEA3, MAGEA10, MAGEB1, CT7/MAGEC1, CT10/MAGEC2, NY-ESO-1, SSX1, SSX2, SSX4, CT16/PAGE5, HOM-TES-85/LUZP4,
BRDT/CT9, CTp11/SPANXC, OY-TES-1/ACRBP, CTAGE1, CT15/ADAM2,
CSAG2, IL13RA2, HCA661/E2F-like/TFDP3). mRNA sequences corre-
sponding to NY-ESO-1 and BRDT/CT9 aligned in more than one
location in the genome, suggesting an event of gene duplication that
resulted in two identical copies [43]. Therefore the 20 CTAs were
represented in our Transcriptome Database (see Materials and
methods) by 23 clusters all of them containing at least one EST.
CTA clusters were generally composed by a small number of ESTs.
Fifty percent of the clusters contained less than 10 ESTs, conﬁrming
the restricted expression pattern of these CTAs. Surprisingly, 85% of
the CTA clusters contained ESTs derived from normal tissues and only
39.1% of these clusters contained ESTs derived from testis cDNA
libraries. Indeed, only 10% of the CTA clusters were composed exclu-
sively by ESTs derived from testis and tumor cDNA libraries as one
would expect by the characteristic expression pattern of CT genes.
Moreover, the majority of the 23 CTA clusters contained ESTs derived
from cDNA libraries of an unknown tissue source.
Improving the transcriptome database
The presence of ESTs derived from normal tissues in CTA clusters
can be explained, in part, by the existence of large gene families for
most CTAs with high similarity between all members and by the fact
that somemembers of CTA gene families have a ubiquitous expression
pattern that do not correspond to that of a characteristic CT gene. ESTs
corresponding to members of these gene families align to multiple
regions in the genome and are represented in different clusters,
therefore explaining the presence of ESTs derived from normal tissues
in known CTA clusters. To overcome this problem, multiple align-
ments were excluded from the Transcriptome Database by giving a
quality score for each alignment as described in Materials and
methods and by keeping in the database only the alignments with
the highest score for each sequence.
The presence of a signiﬁcant number of ESTs derived from normal
tissues and unknown tissue source in CTA clusters can be also
explained by an erroneous description of the tissue source of cDNA
libraries submitted to GenBank. To overcome this problem we have
manually curated cDNA library descriptions and contacted the groups
responsible for submissions when information was misleading or
unavailable (Supplementary material 1). We kept in our database only
EST sequences derived from cDNA libraries with a reliable and
informative description.
Selection of candidate clusters corresponding to novel CT genes
The EST composition of clusters corresponding to known CT genes
was also used to deﬁne parameters for computational selection of
additional clusters corresponding to novel CT genes. After the
improvements made in the Transcriptome Database, we observed
that 20% of the CT gene clusters were composed by ESTs derived from
normal testis and tumor cDNA libraries, 10% of the CT gene clusters
were composed only by testis ESTs and 5% were composed only by
tumor ESTs. Moreover, 65% of CT gene cluster contained a small
percentage of ESTs derived from normal tissues, probably due to the
spurious expression of some of the CT genes in normal tissues as has
been previously reported [22].
Based on this information, we generated 3 independent lists of
candidates: i) clusters composed only by ESTs derived from testis
cDNA libraries, ii) clusters composed by ESTs derived from testis and
tumor cDNA libraries and iii) clusters composed only by ESTs derived
from cDNA libraries of tumoral origin. Clusters composed mainly by
ESTs derived from testis and tumors, but containing a small
percentage of ESTs from normal tissues, were not selected because,
after analyzing clusters corresponding to known CT genes, we were
unable to establish a reliable cut-off for the presence of these ESTs.
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by at least one spliced EST that aligned non-contiguously to the genome
sequence because EST data contain a signiﬁcant fraction of DNA
contaminant sequences. It should be noted, however, that this was a
conservative approach that might have excluded candidate clusters
composed exclusively by 3′ unspliced ESTs. Although legitimacy of 3′
ESTs can be attested by the occurrence of a bona-ﬁde polyadenylation
signal and the presence of a poly(A) tail, we decided to undertake such a
conservative approach because poly(A) tails are frequently trimmed
from EST sequences submitted to dbEST and the identiﬁcation of
polyadenylation signals is usually hampered by the low quality of the
sequences near poly(A) tails and to the low signal/background ratio in
the identiﬁcation of reliable polyadenylation signals.Fig.1.mRNA expression pattern of the ﬁve candidates in normal tissues (A) and tumor cell lin
GAPDH ampliﬁcation was used as positive control for cDNA synthesis. NO: cDNA-negative cA total of 1184 candidate clusters were computationally selected of
which 830 were composed only by ESTs derived from normal testis
cDNA libraries, 68 were composed by ESTs derived from normal testis
and tumors and 286 were composed only by ESTs derived from tumors
(Supplementary material 2). We then randomly selected a subset of
candidate clusters for validation of their expression pattern by RT-PCR.
Cluster size requirements were not imposed as criterion for cluster
selection because, as revealed by our previous analysis, clusters
corresponding to known CT genes were composed by a small number
of ESTs and establishment of cluster size requirements would probably
eliminate good CT candidates. Clusters selected for experimental vali-
dation were manually inspected to conﬁrm the presence of conserved
donor and acceptor splicing sites (GT/AG). A total of 23 candidates fromes (B). Southern blot of RT-PCR products ampliﬁed with each candidate speciﬁc primers.
ontrol.
156 F. Bettoni et al. / Genomics 94 (2009) 153–160each of the 3 lists were randomly selected for validation and we
extended our analysis to 23 additional candidates from the testis only
list, since all candidates validated in the initial round of RT-PCRs were
derived from this particular list (Supplementary material 3).
Expression analysis of candidate clusters corresponding to novel
CT genes
Expression pattern of candidate clusters was determined by RT-
PCR using cDNA from 21 normal tissues, 17 tumor cell lines and 160
samples derived from 9 different types of tumors. RT-PCR conditions
were standardized using testis cDNA as template. Few modiﬁcations
including changes in the annealing temperature and MgCl2 concen-
tration and addition of PCR enhancers such as betaine were intro-
duced when ampliﬁcation was not achieved. Ampliﬁcations were
achieved for 70 out of the 92 initially selected candidates and ampli-Fig. 2. Expression analysis of the 5 Cﬁed fragments were sequenced to conﬁrm their speciﬁcity (Supple-
mentary material 3).
Six candidates (CAND1.1, CAND1.6, CAND1.19, CAND1.23,
CAND1.26 and CAND1.29) were exclusively expressed in testis
among all 21 normal tissues analyzed, ﬁve candidates (CAND1.8,
CAND1.17, CAND1.25, CAND1.30 and CAND1.32) were expressed in
testis and normal brain and one candidate (CAND1.11) was expressed
in normal testis and placenta. The expression of six of these initial
candidates (CAND1.1, CAND1.11, CAND1.17, CAND1.19, CAND1.26 and
CAND1.29) with a restricted expression in normal tissues was also
detected in at least one tumor cell line (Fig. 1).
During this expression evaluation step, CAND1.1 was described as a
novel CTA (PASD1) frequently expressed in B-cell lymphomas and
capable of eliciting humoral immune response in 40% of those patients
[23]. Although we cannot claim the discovery of PASD1 as a novel CTA,
we decided to evaluate its expression in different types of solid tumorsT candidates in tumor samples.
Table 2
Frequency of anti-PASD1, -GASZ and -FAM46D antibodies in plasma samples from
cancer patients.
Tumor Antibody response (%)
PASD1 GASZ FAM46D
Cervix 1/31 (3.2) 0/31 (0.0) 0/31 (0.0)
Lung 0/19 (0.0) 0/19 (0.0) 1/19 (5.2)
Colon 0/18 (0.0) 0/18 (0.0) 0/18 (0.0)
Glioblastoma 2/25 (8.0) 0/25 (0.0) 1/25 (4.0)
Total 3/93 (3.2) 0/93 (0.0) 2/93 (2.1)
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support the role of PASD1 as a therapeutic target for different tumor
types other than B-cell lymphomas.
Expression analysis of PASD1 and the 4 CT candidates (CAND1.11,
CAND1.19, CAND1.26 and CAND1.29) exclusively expressed in testis or
testis and placentawas then carried out in 160 samples derived from 9
different histological types of tumors (Fig. 2). PASD1 was expressed in
41% (65/160) of tumor samples with the highest frequency of
expression observed in glioblastomas (70%). CAND1.11 was expressed
in 65% (104/160) of tumor samples with the highest expression
frequency in lung tumors (93%). CAND1.19 was expressed in 20% (31/
155) of tumor samples with the highest expression frequency in
cervical tumors (50%). CAND1.26 was expressed in 24% (38/160) of
tumor samples and was predominantly expressed in lung tumors
(50%). CAND1.29was expressed in 18% (28/156) of the tumor samples
being more frequently expressed in gastric tumors (33.3%).
Candidate clusters corresponding to novel CT genes
Two (CAND1.19 and CAND1.26) out of the four CT genes are
represented by a full-length mRNA sequence and code for a known
human protein (Table 1). Candidate CAND1.19 corresponds to the
ASZ1 or GASZ gene (Germ cell-speciﬁc ankyrin, SAM and basic leucine
zipper domain containing protein 1) that maps to chromosome 7q31.2
and codes for a predicted protein of 475aa containing four ankyrin
repeats and a SAM (Sterile AlphaMotif) and a bZIP domains. The GASZ
protein is localized in the cytoplasm of spermatocytes and oocytes at
different stages of differentiation [44]. Based on its functional
domains, GASZ may act as a signaling protein and/or transcriptional
regulator during germ cell maturation and early embryogenesis.
Candidate CAND1.26 corresponds to FAM46D gene (Family with
sequence similarity 46, member D) mapping to chromosome Xq21.1
and encoding a 389aa protein with unknown function.
The remaining 2 CTgenes (CAND1.11 and CAND1.29)were not repre-
sented by a full-length mRNA sequence at the time of this analysis and
their partial 3′ sequenceswere extended towards their 5′ endusingRACE
(Rapid Ampliﬁcation of cDNA Ends). Four distinct 5′ RACE fragments
corresponding to CAND1.11 splicing variants were obtained (GenBank
accession nos. EF537578, EF537579, EF537580, and EF537581) and a
single RACE fragment (GenBank accession no. EF537582] was generated
for CAND1.29. After assembling a consensus sequence for CAND1.11 and
CAND1.29 using the original 3′ ESTs and the RACE fragments, no open
reading frames (ORF) longer than 110aa were identiﬁed.
Serological analysis of PASD1 and CTA candidates
The presence of antibodies against the recombinant his-tagged
proteins corresponding to PASD1, GASZ (CAND1.19) and FAM46D
(CAND1.26) genes was then evaluated by ELISA in plasma samples
from cancer patients. Samples from19 lung cancer patients, 31 cervical
cancer patients,18 colorectal cancer patients, 25 glioblastoma patients
and 50 healthy blood donors were used for the ELISA screening
(Table 2). Antibodies against PASD1 and FAM46D were detected in
3.2 and 2.1% of all plasma samples from cancer patients, respectively. A
humoral immune response against GASZ could not be detected among
all plasma samples analyzed. Anti-PASD1 antibodies were detected
in plasma samples from patients with cervical cancer (3.2%) andTable 1
Gene name and chromosome location corresponding to each of the ﬁve CT candidates.
Candidate Reference sequence Gene name Chromosome region
CAND1.1 BI458651 PASD1 Xq28
CAND1.11 AI652043 – 11p15.4
CAND1.19 BG771896 GASZ 7q31.2
CAND1.26 BG722950 FAM46D Xq21.1
CAND1.29 AA451827 – Xq23glioblastoma (8.0%) while anti-FAM46D antibodies were detected in
samples from lung cancer (5.2%) and glioblastoma (4.0%) patients.
Discussion
CTAs are considered promising candidates for the development of
therapeutic cancer vaccines. However, continued progress in the
development of such vaccines will depend on the identiﬁcation of a
large repertoire of CTAs that could be incorporated in polyvalent
cancer vaccines designed to overcome tumor heterogeneity and
immune escape.
In the present work, we have used the publicly available human
genome and ESTs sequences to identify novel CT genes. By examining
the EST tissue composition of clusters corresponding to known CT
antigens, we were able to detect and overcome initial limitations of
our in silico approach. We believe that three major aspects of our in
silico analysis have signiﬁcantly contributed to improve our candidate
selection and expression validation efﬁciency. The ﬁrst critical aspect
was the use of the human genome sequence as a scaffold for EST
clustering, since it allowed us to exclude multiple alignments related
to the existence of large gene families among CTAs and to correctly
cluster ESTs corresponding to each family member.
Manual curation of cDNA library descriptions available in GenBank
was the second important aspect of our work. Unfortunately, at the
time of this analysis there was no common structured vocabulary to
describe cDNA libraries and descriptions were generally poor and
imprecise, leading to the misclassiﬁcation of the libraries when
considering the tissue source and pathologic characteristics. During
the course of this work, Kelso et al. [45] developed eVOC, a controlled
vocabulary for gene expression data that consists of four orthogonal
controlled vocabularies describing the anatomical system, cell type,
pathology and developmental stage for each cDNA library. Using eVOC
the authors have curated and annotated 7016 cDNA libraries
represented in dbEST. In attempt to complement and improve our
own manual curation, eVOC annotation was integrated to our
database, however no major improvements were observed in our
candidate selection.
The analysis of EST composition of CTA clusters was the third
important aspect of our analysis, since it allowed us to deﬁne broader
parameters for the selection of additional EST clusters corresponding
to CT gene candidates. As opposed to other in silico analysis, we did
not limit our selection to clusters composed by ESTs derived from
normal testis and tumors. Indeed, the selection of clusters composed
exclusively of ESTs derived from normal testis was critical for our
validation efﬁciency, since all CT genes we have identiﬁed in this work
were represented in our Transcriptome Database by normal testis ESTs
only.
Using this supervised in silico analysis, we were able to select a
total of 1184 candidate clusters and the expression pattern of a subset
of these clusters was validated by RT-PCR in normal tissues and in a
large collection of tumor cell lines and tumor specimens. Our
computational approach was conservative and this number is
probably underestimated since we excluded clusters containing a
small percentage of ESTs from normal tissues and clusters exclusively
composed by bona-ﬁde 3′ unspliced ESTs from our analysis.
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broad expression in different types of tumors were identiﬁed.
Southern blot analysis of RT-PCR products was used to improve the
sensitivity and speciﬁcity of our analysis. Our four CT genes are
frequently expressed in melanomas and lung tumors, which are
classiﬁed as tumors with a high CT gene expression frequency [3,22],
but they are also frequently expressed in tumors considered as mode-
rate and low CT expressors such as breast, prostate and colon tumors,
respectively.
Two of these validated CT genes (CAND1.11 and CAND1.29) were
represented by partial 3′ sequences andwere extended towards their 5′
end using RACE. After assembling a consensus sequence for CAND1.11
and CAND1.29 using the original 3′ ESTs and the RACE fragments, no
open reading frames (ORF) longer than 110aawere identiﬁed. Although
we cannot exclude the possibility thatwe still have partial sequences for
these transcripts, it is tempting to speculate that these CT genes might
belong to the growing class of non-coding regulatory RNAs. To our
knowledge, these are the ﬁrst descriptions of non-coding CT genes
and despite the fact that they cannot be considered target for cancer
immunotherapy the role of these non-coding CT genes in the tumo-
rigenic process deserves further evaluation.
While this work was in progress, Liggins et al. [23] described
PASD1 (CAND1.1) as a novel CTA eliciting humoral response in
patients with diffuse large B-cell lymphomas (DLBCL). Subsequently
studies have demonstrated the presence of anti-PASD1 antibodies in
35% (6/17) of sera from patients with acute myeloid leukaemia (AML)
and 6% (1/16) of sera from patients with chronic myeloid leukaemia
(CML) [46]. In addition, Guinn et al. [46] demonstrated that
monocyte-derived dendritic cells electroporated with PASD1 mRNA
could stimulate autologous T-cells to proliferate. The PASD1 gene
maps to chromosome Xq24–28. PASD1 predicted proteins have in
common a PAS (Per ARNT Sim) domain, a putative leucine zipper and
nuclear localization signal, suggesting that they may act as transcrip-
tion factors. Although we cannot claim the discovery of PASD1 as a
novel CTA, information presented in this manuscript on the high
frequency of PASD1 expression in different types of solid tumors and
immunogenicity in patients with cervix tumors and glioblastomas
supports PASD1 as a promising target for cancer immunotherapy.
Finally, we were able to detect speciﬁc antibodies against the
FAM46D protein (CAND1.26) in plasma samples from patients with
lung tumors and glioblastomas. As many other CTAs, FAM46D is
located on chromosome X and is a member of a large family of pro-
teins with unknown function. Due to its restricted expression pattern
and immunogenicity FAM46D represents a novel target for cancer
immunotherapy.
To our knowledge, this is the ﬁrst report that combined in silico
and experimental evaluation of gene expression with serological
analysis of cancer patients to identify novel CT antigens. Based on our
results, FAM46D and PASD1 should be considered novel targets to the
development of a cancer immunotherapy. Further experiments are
ongoing to evaluate their function and immunogenicity in other
tumor types.
Materials and methods
Transcriptome database
Human ESTs available at dbEST (dbEST release 070502) and mRNA
sequences from UniGene release 153 were aligned to the masked
human genome sequence (NCBI, build 29) by using pp-Blast [47], an
implementation of MEGABLAST for a parallel cluster. The parameters
used in MEGABLAST were: -f T -J F -F F -W 24. The MEGABLAST output
was parsed and a MySQL database was loaded with alignments
coordinates and identities. Information about the tissue origin of each
expressed sequence was obtained after manual curation of cDNA
library descriptions available at dbEST (Supplementary material 1)and was also uploaded in the database. Spurious and multiple
alignments were excluded from the Transcriptome Database by
using an additional set of alignment criteria. These included a
minimum identity of 93%, coverage (percentage of sequence length
aligned) greater than 45% for EST and coverage greater than 55%
for mRNAs. Sequences mapping to more than one location on the
genome were given a score for alignment quality. A higher score
was associated with a higher identity and coverage. Only the align-
ments with the highest scores were kept in the database. Clustering
of the expressed sequences was based on their genomic coordinates
as described by Galante et al. [48]. Brieﬂy, if two sequences shared
at least partially the same gene structure (exon/intron boundaries)
they were joined into the same cluster. If no exon/intron boundary
was deﬁned, a sequence had to have at least a 100-bp overlap with
another sequence at the genome level to be added to the respective
cluster.
Cluster selection and manual inspection
By querying the Transcriptome Database, we were able to select
clusters composed by spliced ESTs derived from testis and/or tumoral
cDNA libraries. Selected clusters were manually inspected to conﬁrm
the splicing structure by checking the presence of conserved donor
and acceptor splicing sites (GT/AG) and to exclude those that corres-
pond to known CT antigens. Manual inspection was carried out using
the BLAT interface provided by UCSC Genome Browser (http://
genome.ucsc.edu/).
Cell lines and tumor samples
Human tumor cell lines A172 and T98G (glioblastoma); FaDu
(squamous cell carcinoma); SW480 (colorectal adenocarcinoma);
A2058 and SKmel-28 (malignant melanoma); DU145 and PC3
(prostate carcinoma); HeLa and CasKi (cervix adenocarcinoma);
MCF-7 and MDA-MB-436 (breast ductal carcinoma); HL-60 (acute
promyelocytic leukaemia); H1155 and H358 (lung carcinoma);
SCaBER (transitional cell carcinoma) and SAOS-2 (osteosarcoma)
were obtained from American Type Culture Collection (Manassas,
VA). Tumor samples were collected from patients treated at Hospital
A.C. Camargo. All samples were collected after explicit informed
consent and with local ethical committee approval.
RNA, cDNA synthesis and RT-PCR
Total RNA from cell lines and tumor samples was extracted by the
conventional CsCl guanidine thiocyanate method [49]. Total RNA from
21 normal human tissues (testis, lung, prostate, small intestine, breast,
brain, fetal brain, cerebellum, heart, uterus, placenta, colon, fetal liver,
thymus, salivary gland, spinal cord, kidney, spleen, skeletal muscle,
stomach and trachea) was purchased from Clontech (Palo Alto, CA).
RNA samples were checked for integrity by agarose gel electrophoresis
and 2 μg were used for cDNA synthesis. Reverse transcription was
performed with DNA-free RNA by using SUPERSCRIPT II Reverse
Transcriptase (Invitrogen) and oligo(dT) (GE Healthcare). Primers
used for expression analysis (Supplementary material 2) were
designed in different exons using the Primer3 program. RT-PCRs
were carried out in 25 μl containing 1 μl of ﬁrst-strand cDNA, 1× Taq
DNA polymerase buffer (Invitrogen), 1 mMMgCl2, 0.1 mM dNTPs (GE
Healthcare), 1 U of Taq DNA polymerase (Invitrogen) and 0.3 μM of
each primer. Ampliﬁcation conditions were: initial denaturation for
4 min at 94 °C followed by 40 cycles of 45 s at 94 °C, 45 s at 60 °C and
1min at 72 °C, with a ﬁnal extension step of 6min at 72 °C. RT-PCRwas
carried out in duplicates and triplicates were used to solve
discrepancies between duplicates. RT-PCR products were analyzed
on 8% silver-stained polyacrylamide gel and sequenced to conﬁrm
their speciﬁcity. RT-PCR products for candidates CAND1.1, CAND1.11,
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gels followed by Southern blot analysis.
RACE (rapid ampliﬁcation of cDNA ends)
5′-RACE was performed on normal testis poly(A)+ RNA by using
the Marathon cDNA Ampliﬁcation Kit (Clontech, Palo Alto, CA).
Ampliﬁcations reactions were performed in 25 μl by using 2.5 μl of
cDNA, 0.2 mM dNTPs, 0.2 μM speciﬁc primer (RACE5′/CAND704, 5′
GATTTTCCAGACCTTGTCCAAGCTCC3′, RACE5′/CAND1001, 5′CACACA-
GAATGCCGCTCGCTAGGAG3′), 0.2 μM adaptor primer, 1 U of Advan-
tage Taq DNA polymerase. PCR conditions were: 5 cycles of 5 s at 94 °C
and 3 min at 72 °C, 5 cycles of 5 s at 94 °C, 10 s at 70 °C and 3 min at
72 °C, and 25 cycles of 5 s at 94 °C, 10 s at 68 °C and 3 min at 72 °C.
Nested PCR was carried out by using 5 μl of the ﬁrst reaction product
diluted 50×, speciﬁc nested primer (RACE5′/CAND704N, 5′
GTGGCCAACTGAGCTGCAGACTTCCC3′, RACE5′/CAND1001N, 5′
GATGTTTCCTCTTAGGCCTCTTCTCC3′) and nested adaptor primer. PCR
conditions differ from the ﬁrst reaction only by using 20 cycles. PCR
products were analyzed on agarose gels, cloned and sequenced as
described above.
Recombinant protein expression
CAND1.1 (773aa), CAND1.19 (475aa) and CAND1.26 longest ORFs
(389aa) were ampliﬁed from normal testis cDNA using the following
primers: CAND1.1F (5′- CGGAATTCATGAAGATGAGAGGGGAAAAG-3′)
and CAND1.1R (5′- CCCAAGCTTTTAGCACGGCTTATTTGAGTC-3′);
CAND1.19F (5′- GATATCATGGCGGCGAGCGCGCTGCGA-3′) and
CAND1.19R (5′- CGGAATTCTTATTTCCTCTGGAAAGTTAG-3′);
CAND1.26F (5′- CGGAATTCATGTCTGAAATCAGATTCACC-3′) and
CAND1.26R (5′- CCCAAGCTTTTAACTCATACCATTTGATCC-3′). The PCR
products corresponding to CAND1.1 and CAND1.26 were digested
with EcoRI (New England Biolabs) and HindIII (New England Biolabs)
and cloned into the expression vector pET28a (Stratagene, La Jolla,
CA). The PCR product corresponding to CAND1.19 was digested with
EcoRV (New England Biolabs) and EcoRI (New England Biolabs) and
cloned into the expression vector pET32a (Stratagene, La Jolla, CA).
After sequencing, recombinant plasmids were transformed into
Escherichia coli BL-21 Rosetta. After induction with 0.4 mM isopropyl
β-D-thiogalactoside at 37 °C for 4 h, recombinant proteins fused with
a 6His-tag were puriﬁed by Ni2+ afﬁnity chromatography by using
the NiNTA agarose resin (Invitrogen). The puriﬁed protein was
analyzed by Western blot using an anti-His-tag monoclonal antibody
(GE Healthcare) to conﬁrm the puriﬁcation efﬁciency.
Antibody response in cancer patients
Plasmas were obtained from patients treated at Hospital A.C.
Camargo. All samples were collected after explicit informed consent
andwith local ethical committee approval. In addition, plasma samples
from 50 healthy individuals were collected from blood donors at the
Hospital A.C. Camargo Blood Center. Antibodies against CAND1.1,
CAND1.19 and CAND1.26 recombinant proteins were determined by
direct ELISA (Enzyme-Linked ImmunoSorbent Assay). Microplates
were coated with 50 μl of the recombinant protein (5 μg/ml) in
phosphate buffered saline (PBS) pH 7.4 for 2 h at 37 °C. Wells were
blocked with 5% (w/v) skim milk in PBS, washed 3 times with PBS-
Tween (0.1%) overnight at 4 °C, and incubatedwith 50 μl serumdiluted
1:100 in dilution buffer (5%(w/v) skim milk in PBS) for 2 h at 37 °C.
After washing, 50 μl goat anti-human IgG conjugated to horseradish
peroxidase (Sigma) diluted 1:5000 in PBS was used as secondary
antibody for 1 h at 37 °C, followed by washing. Bound secondary
antibody was visualized by the HRP enzymatic reaction using OPD
tablets (Sigma). Absorbance at 492 nm was read on a SpectroCount
analyzer and expressed as optical density (OD) values. All serumsamples were analyzed in triplicates and corrected for background
binding to an irrelevant protein from sugar cane expressed in the same
expression system as CTs recombinant proteins. ELISA cut-off was
established as the mean+2SD of healthy blood donors. Experiments
were carried out in duplicates and a serum sample was considered
positive when reactivity was observed in two independent ELISA
assays. Triplicates were used to solve discrepancies between
duplicates.
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